The global multiomics in drug discovery market is undergoing transformative growth, with projections pointing toward a significant surge in revenue through the forecast period of 2025 to 2034. This expansion is driven by increasing technological advancements, growing demand across pharmaceutical sectors, and a strong push towards data-driven and precision medicine approaches.
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/download-databook/5752
Multiomics refers to the integrated analysis of multiple “omics” data types—such as genomics, transcriptomics, proteomics, and metabolomics—to provide a holistic view of biological processes. In the realm of drug discovery, this integration allows researchers to understand disease mechanisms more comprehensively and predict drug responses with higher precision.
A major application of multiomics is in predicting drug sensitivity, which supports the design of targeted therapies and personalized treatment plans. The fusion of multiomics with artificial intelligence (AI) tools is a powerful trend that is accelerating progress in pharmaceutical R&D.
North America led the global market in 2024 due to robust infrastructure and early adoption of innovative technologies.
Asia Pacific is expected to grow at the fastest rate, driven by investments in biotech and increasing disease burden.
The genomics segment accounted for the largest share by omics type in 2024, whereas metabolomics is projected to grow most rapidly.
Consumables led the market by product and service type, while software solutions are set to expand significantly.
By application, target discovery and validation was dominant in 2024, with precision medicine development expected to exhibit the highest growth.
Pharmaceutical and biotechnology companies were the leading end-users, but contract research organizations (CROs) are anticipated to show the fastest CAGR.
Get All the Details in Our Solutions – Access Report Preview: https://www.towardshealthcare.com/download-sample/5752
In May 2025, Illumina and Ovation.io introduced the world’s largest clinical multiomic dataset derived from 25,000 patients treated with GLP-1 receptor agonists, available for pharmaceutical research.
In July 2024, Element Biosciences secured $277 million in Series D funding to further enhance its multiomics and DNA sequencing platforms.
In June 2025, BioAro Inc. launched the PanOmiQTM platform—a powerful AI-integrated multiomics solution—at the BIO International Convention in Boston.
In January 2025, Enhanc3D Genomics introduced integrated 3D multiomics technologies to accelerate and refine drug discovery efforts.
In April 2025, Abu Dhabi announced the construction of a multiomics research hub, highlighting the city’s growing role in global healthcare innovation.
The vast volumes of omics data being generated today require sophisticated tools to extract meaningful insights. AI techniques—especially natural language processing and machine learning—are essential for analyzing and interpreting complex datasets. These technologies enable researchers to discover causal relationships, streamline drug target validation, and enhance predictive modeling.
Developing a new drug can take up to 15 years and billions in investment. Multiomics, when combined with large biobanks and cutting-edge analytics, is reducing timeframes and enhancing the success rate of new drug candidates.
The use of human data in multiomics raises critical concerns around privacy, data sharing, and informed consent. Regulatory frameworks need to evolve to ensure the responsible use of these technologies.
There is a growing need for robust bioinformatics tools that can integrate, visualize, and interpret complex multiomics data. This presents a major opportunity for software developers and AI solution providers in the biomedical space.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
Genomics dominated in 2024, driven by increased use of next-generation sequencing and global initiatives like the UK’s 100,000 Genomes Project.
Metabolomics is gaining traction as it enables identification of diagnostic and therapeutic biomarkers, especially for complex diseases like cancer and IBD.
Consumables accounted for the largest share due to high usage in sample prep and analytical procedures.
Software is expected to see the highest growth, given its pivotal role in data interpretation and visualization.
Target Discovery and Validation led in 2024, supported by advances in computational biology and systems analysis.
Precision Medicine is the fastest-growing application, as it leverages integrated omics data to create individualized treatment strategies.
Pharmaceutical and biotechnology firms remain the largest adopters of multiomics due to their focus on innovation and personalized drug pipelines.
Contract Research Organizations (CROs) are emerging as essential players, offering global regulatory support and trial management services.
The U.S. continues to dominate due to significant government and private investment, well-developed infrastructure, and a strong ecosystem of genomics research institutions. With projected healthcare spending expected to exceed $6 trillion by 2028, the region remains central to innovation in multiomics.
Canada has invested over $1.6 billion in genomics research through Genome Canada and will further inject funds under its Canadian Genomics Strategy starting 2024–2025. The country is positioning itself as a leader in large-scale multiomics research.
Countries such as China, India, and Japan are aggressively adopting omics technologies. Government support, expanding biotech sectors, and a rising burden of chronic diseases are contributing to rapid market growth.
Germany introduced the Medical Research Act to streamline clinical trials and improve its position as a medical research hub.
The UK announced long-term R&D budgets in 2025 to secure funding for top research institutions and emerging priorities.
The global multiomics in drug discovery market is entering a phase of unprecedented innovation. With AI integration, collaborative research efforts, and international investments in infrastructure, the sector is poised to revolutionize the way we understand and treat diseases. Stakeholders across biotech, pharma, and digital health must align to harness the full potential of multiomics for the future of precision medicine.
Source : https://www.towardshealthcare.com/insights/multiomics-in-drug-discovery-market-sizing
The global single-cell biotherapeutics market is on a robust growth trajectory, with projections indicating a surge into the hundreds of… Read More
The global healthcare ecosystem is undergoing a profound transformation. One of the most pivotal shifts is the surge in demand… Read More
The global clinical genomics market is set to grow from USD 1.06 billion in 2024 to an impressive USD 5.34… Read More
The global AI in medical billing market is undergoing a significant transformation, poised to grow from USD 3.73 billion in… Read More
The global preclinical advanced cell models market is rapidly evolving, fueled by the increasing demand for accurate, human-relevant testing platforms… Read More
The digital revolution is reshaping healthcare education across the globe. With the integration of virtual platforms, AI, and immersive technologies,… Read More